Short Interest in Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) Rises By 823.1%

Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHYGet Rating) was the recipient of a large increase in short interest in the month of May. As of May 15th, there was short interest totalling 12,000 shares, an increase of 823.1% from the April 30th total of 1,300 shares. Based on an average trading volume of 340,500 shares, the days-to-cover ratio is currently 0.0 days.

Separately, Jefferies Financial Group upgraded shares of Santen Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Friday, April 15th.

Shares of SNPHY traded down $0.05 during trading hours on Wednesday, hitting $8.02. 119,990 shares of the stock were exchanged, compared to its average volume of 107,594. Santen Pharmaceutical has a fifty-two week low of $7.65 and a fifty-two week high of $15.70. The business has a 50-day moving average of $9.00 and a 200-day moving average of $10.98.

About Santen Pharmaceutical (Get Rating)

Santen Pharmaceutical Co, Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products to treat glaucoma and ocular hypertension, such as DE-111, which is in Phase III clinical trial; DE-117 in Japan; DE-126 that is in Phase IIb clinical trial; DE-128 in Europe, as well as is in Phase II/III clinical trial in the United States; and DE-130A that is in Phase III clinical trial.

See Also

Receive News & Ratings for Santen Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Santen Pharmaceutical and related companies with's FREE daily email newsletter.